Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3977067 | Brachytherapy | 2012 | 6 Pages |
Abstract
This is the first published report of the use of HDR brachytherapy as monotherapy in one fraction for patients with favorable-risk prostate cancer. This protocol is feasible and very well tolerated with low GU morbidity, no gastrointestinal toxicity, and the same level of low-dose-rate biochemical control at 32 months.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Pedro J. Prada, Isabel Jimenez, Herminio González-Suárez, José Fernández, Covadonga Cuervo-Arango, Lucia Mendez,